17 November 2026
originally posted on LinkedIn.
by Amina Larbi, Pascale Boulet and Esteban Burrone
As we celebrate the 10th anniversary of MedsPaL, the Medicines Patents and Licences database, we reflect on why it was established and how it helped to radically simplify access to patent information for essential medicines in low- and middle-income countries.
The patent system is based on a simple concept. In exchange for disclosing details of an invention to the public, an inventor may receive exclusive rights over that invention for a limited period. Transparency is therefore at the heart of the patent system. The very word “patent” means that something is open, clear or explicit. What is being patented, and where, should therefore be open, clear or explicit. The reality, however, turns out to be far more complex.
As the Medicines Patent Pool was being established by Unitaid in 2010 to negotiate licences for patented HIV medicines, a key question that emerged was which patents needed to be licensed. To answer it, we needed to know which medicines were patented, where and until when. Finding an answer to that simple question proved to be extremely challenging.
Identifying the patents covering each medicine was the first hurdle.A word search on patent office websites returned hundreds of potentially relevant patents for each medicine, most of which referred to the medicine in the description or the claims but do not cover the medicine itself. Worse, the most important patent on a medicine, the patent covering the molecule itself, would not be found because patent applications are usually filed before the molecule has a name. Most free online databases (such as those from patent offices) do not enable searches using chemical structures.
Once we succeeded in identifying the relevant patents, the next big challenge was to find out whether equivalent patents had been filed in other countries, in particular, low- and middle-income countries (LMICs). This required searching the records of approximately 140 patent offices. However, many patent offices do not maintain searchable online databases (and even less so 10 years ago). Even when such databases exist, they are often difficult to navigate, available only in national languages, or limited to showing that a patent had been filed or granted without indicating whether it remained in force. Almost none indicated expiry dates, and differences in national rules meant that calculating those dates was not always straightforward.
Our initial intention was not to build a database. We began by collecting information on where individual HIV medicines were patented to meet MPP’s own licensing needs, compiling the results in a simple spreadsheet. Almost immediately we began receiving enquiries from procurement agencies, global health organisations and others. The questions varied, but they essentially came down to the same thing: is medicine X patented in country Y?
“We do not want to infringe on existing patents”, we were told by public health officials or entities charged with the procurement of medicines in LMICs, “but we are often unable to know whether a medicine is patented or not”. Explaining that the answer was complex was not enough. If transparency was fundamental to the patent system, there needed to be a transparent and practical way to identify the national patents relevant to a medicine and determine whether they remained in force.
What was needed seemed clear to us. Each medicine has a standard generic name, known as an International Non-proprietary Name (INN). This is a name like paracetamol, or in the field of HIV, zidovudine, lamivudine or efavirenz. What was needed was a resource that would enable people to search for patents by INN and by country, and obtain a list of relevant patents, along with their status and expected expiry dates.
Building this resource was possible, but it required working country by country and patent by patent. We used multiple strategies to gather that information. The European Patent Office (EPO) and the World Intellectual Property Organization – WIPO supported us through their online tools and, in WIPO’s case, by facilitating contact with certain patent offices. Other online tools, including the FDA Orange Book and Health Canada | Santé Canada patent register, also helped. Some patent offices provided the information directly to us on request and others signed memoranda of understanding (MOUs) with MPP to share data regularly. Separately, the Indian Patent Office requirement to applicants to disclose corresponding patents in other jurisdictions, helped us significantly. In certain countries, we collected the data directly through local patent agents or civil society organisations.
The result was the MPP Patent Status Database, a table covering 24 HIV medicines in 88 countries. It was initially shared with procurement agencies and other global health stakeholders and was first published on MPP’s websitein April 2011.
In 2016, the table became a large-scale searchable database: MedsPaL. As MPP’s mandate expanded beyond HIV to other disease areas, so too did the range of information that MPP collected and that could be made available. MedsPaL therefore grew to include patented medicines from the WHO Model List of Essential Medicines, irrespective of disease area, as well information on licences covering LMICs and on regulatory data exclusivity.
MedsPaL was launched in October 2016 on the sidelines of WIPO’s General Assembly, at a side event that included the signature of MOUs with the European Patent Office and INAPI Chile, the Chilean patent office. At launch, it included information on 35 medicines, 4,000 patents or patent applications and 30 licences. 10 years later, it covers 194 medicines, along with 23 other health products or technologies, 33,800 patents or patent applications and 86 licences. The scale of the database has expanded significantly.
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of innovative medicines and other health technologies for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed health products and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 23 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, one antiviral treatment for influenza, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada and Coeffient Giving. MPP’s activities in technology transfer are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, the Government of Flanders and SDC.